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How to use FDA drug approval documents for evidence 
 syntheses
Aviv Ladanie,1,2 Hannah Ewald,1,2,3 Benjamin Kasenda,1,4 Lars G Hemkens1
Evidence syntheses may benefit 
from using aggregated clinical trial 
information in approval documents 
published online by the US Food and 
Drug Administration (FDA). We provide 
practical guidance on how to access 
and use this source of information 
for evidence syntheses on treatment 
effects of drugs and therapeutic 
biologics.
Publicly accessible approval documents published by 
the US Food and Drug Administration (FDA) provide 
important insights into reporting biases in articles 
published in peer reviewed medical journals,1-4 but 
the FDA data can also be used to directly minimise the 
impact of such biases on the results and conclusions in 
evidence syntheses,5 obtain information not disclosed 
in published clinical trials reports,6 and identify 
unpublished clinical trials to increase precision of 
effect estimates.7
For example, almost 20 years ago, Man-Son-
Hing and colleagues5 showed that incorporating 
unpublished trials into a meta-analysis on quinine 
for nocturnal leg cramps substantially reduced 
the estimated efficacy. The bias occurred because 
almost all published trials had larger effects than 
the unpublished studies. Similarly, Turner and 
colleagues found that 22 (31%) of 71 trials discussed 
in FDA approval documents of 12 antidepressants 
were not published, and that publication was closely 
associated with results favouring the experimental 
drugs.1 Hart and colleagues showed that updating 
meta-analyses with unpublished trial data from FDA 
approval documents changed drug efficacy estimates 
in 38 of 41 cases (93%) towards both lower and higher 
efficacy.4 Rising and colleagues not only revealed that 
approval trials are often unpublished, in particular 
when they suggest unfavourable outcomes for the 
experimental intervention, but also that the published 
information is incomplete because results were 
omitted from the papers.2 MacLean and colleagues, 
on the other hand, demonstrated that incorporating 
unpublished trial data in meta-analyses does not 
necessarily change treatment effect estimates.7 
McDonagh and colleagues show various examples 
where information from FDA documents would alter 
conclusions of drug effectiveness reviews, not only by 
identifying unpublished studies, but also by providing 
unpublished information on benefits and harms 
found in published trials and by reporting results of 
independent analyses conducted by the FDA.6
Overall, such examples illustrate that unpublished 
FDA trial data have the potential to change the 
results of evidence syntheses and can provide useful 
information that would otherwise be unavailable.6 8 
It may help to better understand the strengths and 
weaknesses of a trial that only a regulator could 
discover, given the regulator’s access to the original 
study data and the original trial protocols (drug 
developers must submit the trial protocols before they 
initiate the approval trials9).
However, regulatory data are rarely used in 
evidence syntheses. A survey estimated that only 24 
of 794 Cochrane reviewers (3%) who had searched for 
unpublished clinical trials had gathered information 
from health authorities.10 The survey authors 
hypothesise that “some authors might not be aware of 
the amount of accessible data at regulatory agencies.” 
Others emphasise that FDA approval documents are 
difficult to access and navigate.11-14
Attempts to promote the adoption of regulatory 
data as a viable source of trial information have been 
made recently, including a guide on where and how 
to retrieve FDA approval documents,13 a description 
of the content in FDA and European Medicines Agency 
(EMA) documents,15 and the dissemination of FDA 
approval documents in a more accessible format via 
the recently launched OpenTrialsFDA platform.16
The sheer amount of information encountered in an 
FDA approval document, usually hundreds of pages 
not following the typical structure of medical journal 
articles, may indeed confuse and discourage reviewers 
from using them for evidence syntheses.
Guidance could be provided by the publisher of 
these documents (the FDA), by leading organisations 
advocating for systematic reviews of healthcare 
interventions (particularly the Cochrane Collaboration), 
or by reviewers with experience in using FDA approval 
documents. To our knowledge, the FDA has not 
published any description of the content and structure 
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SUMMARY BOX
•	 There is compelling evidence that published trial information is selectively 
reported and that results not showing favourable effects of the tested 
treatments often remain unpublished
•	 Clinical trial information published by regulatory authorities such as the US 
Food and Drug Administration (FDA) may help to reduce such reporting biases
•	 FDA approval documents are long and do not follow the typical structure of 
medical journal articles, which may discourage reviewers from using them for 
evidence syntheses
•	 Our practical guidance on how to efficiently identify and use approval 
documents to find the relevant information may help promoting the use of 
this valuable data source for evidence syntheses
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of their approval documents, in contrast to the EMA 
and the Australian Therapeutic Goods Administration 
(TGA).17 Neither does the Cochrane Handbook 
provide advice in this direction, and—according to the 
changelog18—the updated version (5.2, June 2017) will 
not be addressing this issue either.19
We have used FDA approval documents in meta-
epidemiological projects, including an ongoing 
analysis of 92 anticancer agents approved by the 
FDA between 2000 and 2016. Here, we share our 
knowledge and describe how we navigate such 
documents efficiently. We also indicate where one 
can expect to find information typically relevant for 
evidence syntheses.
The target users of this guide are mainly authors 
of evidence syntheses who intend to collect and 
synthesise evidence on a given topic in a systematic and 
transparent manner, such as in systematic reviews or 
meta-analyses. This guidance can assist in identifying 
potentially unpublished drug trials, obtaining 
additional information that is unavailable from 
published clinical trial reports, or for cross-checking 
information reported in journal articles. However, it 
does not cover the subsequent indispensable steps of 
evidence synthesis including the quality assessment, 
for which further detailed guidance would be needed.
Provenance of this guidance
We describe the structure and content of FDA approval 
documents based on our experience from various 
meta-research projects, including the ongoing CEIT-
cancer project in which we evaluate the evidence base 
from pre-marketing clinical trials of 92 anticancer 
agents. In this project, we systematically acquire FDA 
approval packages, peruse approval documents, and 
extract trial characteristics as well as treatment effect 
estimates. In addition, we pilot tested the applicability 
of our guidance for several drugs approved for 
neurological, cardiovascular, psychiatric, endocrine, 
and rheumatological disorders and can confirm its 
validity across medical specialties.
The FDA drug approval package
To obtain marketing authorisation for newly 
developed drugs and therapeutic biologic products 
(herein referred to as “drugs”), companies have to 
submit a New Drug Application (NDA) or Biologics 
License Application (BLA) to the FDA and provide 
information about the drug’s quality, safety, and 
efficacy.20 The FDA reviews this information and—for 
drugs that are ultimately approved for marketing—
publishes these reviews (albeit in a form redacted 
of some information) online in the drugs@FDA 
database as PDF documents.21 Documents pertaining 
to a single approved product are organised in 
“approval packages.” There are guidance22 and policy 
documents23 which provide a deeper understanding 
of the FDA processes and evolving procedures. The 
review process is addressed by a “Good Review 
Practice” document within the FDA’s Center for Drug 
Evaluation and Research (CDER) “that discusses any 
aspect related to the process, format, content and/or 
management of a product review.”24
Approval packages are available for prescription 
and over-the-counter drugs as well as “drug-like” 
agents (such as therapeutic biologics, which include 
antibodies, cytokines, growth factors, enzymes, and 
immunomodulators). For a detailed list of what is 
included in the drugs@FDA database, look in the 
“frequently asked questions.”25 Approval documents 
are only sporadically available for drugs approved 
before 1997, and are rarely available for supplemental 
indications (that is, indications approved after a drug 
has received its initial marketing authorisation). 
Approval documents for devices and non-therapeutic 
biologics (such as vaccines, blood, and blood 
products) are not regulated by the CDER and are not 
addressed by this guidance.
Finding and accessing approval packages
We provide guidance on determining whether FDA 
approval packages are available for a given drug 
of interest and how to find the corresponding FDA 
approval package in the supplemental material on bmj.
com (“Part 1: How to access FDA approval packages”).
Document types in approval packages
We are aware of about 20 different document types 
included in FDA approval packages (box 1). The 
medical review is typically most relevant for evidence 
syntheses. The medical reviews (sometimes referred 
to as clinical reviews) usually contain sufficient 
information for identifying and selecting pertinent 
trials as well as main information about clinical 
trial characteristics, statistical analyses and results. 
However, some important details may be revealed only 
after thorough perusal of the entire approval package. 
Since 2016, the medical review document of recently 
approved drugs is often merged with other document 
types in a single “multi-discipline review” document. 
Its content can now be found under the table of contents 
heading “Statistical and clinical evaluation.” If the 
medical review document is missing, incomplete, or 
illegible, or when more in-depth analysis is required, 
the other documents available in the FDA approval 
package may provide further information (see below).
Medical review structure
The medical review document structure has evolved 
over the years, but we identified three general 
document structures (fig 1) used since approximately 
2004. For older drugs and biologicals, there is no such 
consistent document structure.
The actual document structure may deviate slightly 
from these general structures, such as by section heading 
(thus, the section “Review of efficacy” may be titled 
“Efficacy evaluation” or “Integrated review of efficacy”); 
grouping of information (for example, section “Clinical 
pharmacology” may be a subsection of “Significant 
issues from other review disciplines” or it may exist as a 
standalone section); or sequence of sections.
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We generally suggest that reviewers first try to 
locate the table of contents (some older reviews may 
have none) and make themselves familiar with the 
document structure. Sometimes there may be two 
tables of contents in a medical review document. 
This may indicate that the original application for 
marketing authorisation was declined by the FDA 
and that the agency re-evaluated the drug in a second 
review. Triptorelin (Trelstar) is such an example 
(with tables of contents on pages 2 and 41).26 In this 
situation, both medical reviews should be scrutinised 
because the data may differ between the two. Whether 
to use the superseded or the updated version can only 
be decided in the context of the research question. 
An explanation why triptorelin was approved only 
after a second review cycle can be found in the 
regulatory history, usually described in sections titled 
“Introduction,” “Background,” or similar (fig 1).
Data collection
Where to find relevant clinical trials and their 
characteristics
Trials submitted to the FDA to support approval 
are presented and discussed in detail in the purple 
highlighted sections in figure 1. There is typically a 
Box 1: Overview of documents that may be included in FDA approval packages:
1  Administrative documents
2  Approval letter
3  Botanical review
4  Chemistry, manufacturing, and controls review / Chemistry review
5  Clinical pharmacology and biopharmaceutics review / Clinical pharmacology review 
/ Pharmacology review
6  Cross discipline team leader review
7  Drug label*
8  Environmental assessment review
9  Immunogenicity review
10  Medical review / Clinical review*
11  Multi-discipline review*
12  Medication guide / Patient package insert
13  Microbiology review
14  Name review
15  Office director memo
16  Officer/employee list
17  Other review
18  Risk assessment and risk mitigation review
19  Statistical review*
20  Summary review
21  Toxicology review
*Usually most relevant documents for evidence syntheses
~ Post 2015 approvals ~ 2006 to ~2014 approvals ~ 2004 to ~ 2007 approvals
1 Executive summary
2 Therapeutic context
3 Regulatory background
4 Signicant issues from other review
disciplines pertinent to clinical 
conclusions on ecacy and safety
5 Sources of clinical data and review 
strategy
6 Review of relevant individual trials
used to support ecacy
7 Review of eectiveness
8 Review of safety
9 Advisory committee meeting and 
other external consultations
10 Labelling recommendations
11 Risk evaluation and mitigation
strategies (REMS)
12 Postmarketing requirements 
and commitments
13 Appendices
1 Recommendations/risk-benet 
analysis
2 Introduction and regulatory 
background
3 Ethics and good clinical practices
4 Signicant ecacy/safety issues 
related to other review disciplines
5 Sources of clinical data
6 Review ecacy
7 Review of safety
8 Postmarketing experience
9 Appendices
1 Executive summary
2 Introduction and background
3 Signicant ndings from other 
review disciplines
4 Data sources, review strategy 
and data integrity
5 Clinical pharmacology
6 Integrated review of ecacy
7 Integrated review of safety
8 Additional clinical issues
9 Overall assessment
10 Appendices
Provide an overview of the clinical trials submitted 
to the FDA and data on trial characteristics
Describe trial results
Report adverse events
information
Sections with most relevant information for evidence syntheses
Typically less relevant 
for evidence syntheses 
of treatment eects 
of drugs and biologics
Medical review documents of drugs approved before the year 2004 lack a consistent document structure and are not illustrated
Fig 1 | Overview of FDA medical review document structures, with the sections most relevant for evidence syntheses highlighted
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tabular overview with brief information on individual 
trials such as the target population, interventions, 
comparators, outcomes, time frame, setting, and study 
design.
Many trials have multiple trial names or identifiers 
(for example, C0743T09 and PHOENIX 2 in the case 
of ustekinumab (Stelara) (see medical review page 
17)27 and CLEOPATRA, TOC4129g, or WO20698 in 
the case of pertuzumab (Perjeta) (see medical review 
page 30)28). Knowing all trial identifiers may facilitate 
locating the corresponding record on clinicaltrials.gov 
or identifying reports of trials published in journals. 
For example, the pivotal trial of ustekinumab can 
be found as “PHOENIX 2” on PubMed but only with 
detours on clinicaltrials.gov, whereas it can be quickly 
found with its identifier C0743T09 on clinicaltrials.
gov but not in PubMed.
The purple highlighted sections are comparable 
with the methods section in medical journals in 
terms of content, with information on trial design 
(objectives, geographical distribution of sites), trial 
population (eligibility criteria), interventions, trial 
endpoints (definitions, outcome assessment), and 
statistical methods (sample size, calculation of effect 
estimates, and details on interim, subgroup, and 
sensitivity analyses). Excerpts from trial protocols and 
a history of protocol amendments may also be found 
in these sections. They allow, for example, assessing 
pre-specification of endpoints or subgroups. For drugs 
approved before 2007, additional information about 
trial methods (and results) may be available in the 
appendix (fig 1).
Where to find trial results
Results for efficacy endpoints are reported in the pink 
highlighted sections in figure 1. The sections start with 
details of the trial population and enrolment, often 
including a flow diagram, site-specific enrolment 
information, and summary statistics of patient 
characteristics.
Not all trials presented in the purple highlighted 
sections (fig 1) have results, either because they are 
of no relevance for drug approval, they are ongoing, 
or they address a different indication. Such trials 
may still have been used to evaluate the drug’s safety 
profile and to better understand the risk for adverse 
events. The methods and results of the safety review 
are presented in the green highlighted sections 
(fig 1).
We provide a step-by-step instruction (including a 
working example) on where to find relevant clinical 
trials and their characteristics in the supplemental 
material on bmj.com.
Extraction of trial results
Results for various endpoints from several pre-
specified and exploratory analyses are presented in 
the results section of the medical review. The decision 
about which one to choose should be made depending 
on the research aims. We present some general 
examples of the various types of analyses reported 
in medical reviews to facilitate pre-specification 
of the extractions and analyses of interest (box 2). 
We provide a step-by-step instruction (including a 
working example) on where to find trials results in the 
supplemental material.
Further and more detailed information
Additional information on statistical analyses and 
sample size calculation are often provided in the 
statistical review document which is also included 
in FDA approval packages. FDA guidance states: 
“applicants are expected to submit data of high 
quality and make it possible for the FDA to reproduce 
their results. In turn, FDA reviewers should provide 
adequate documentation so that the applicant or 
another data user could reproduce their independent 
findings.”29 The statistical review often includes 
details of such re-analyses, for example: “whether it 
is possible to reproduce the primary analysis dataset, 
and in particular the primary endpoint, from the 
original data source.”29
Sometimes there are comments by the FDA medical 
or statistical reviewer which may be informative for the 
assessment of the quality of evidence—for example, 
to address potential risks of bias or to discuss the 
adequacy of comparator interventions.
Box 2: Diversity of outcome analyses commonly seen in FDA medical reviews
•	 	Intention-to-treat	analyses	versus	per	protocol	or	other	analyses
•	 	Different	data	cut-off-dates	(for	example,	interim	analyses,	final	analyses,	follow-up	
analyses)
•	 	All	study	sites	versus	subsets	of	sites	(for	example,	geographic	region)
•	 	Local	versus	central	outcome	assessments
•	 	Analyses	conducted	by	the	FDA	versus	analyses	conducted	by	sponsors
•	 	Analyses	adjusted	for	covariates	versus	unadjusted	analyses
•	 	Pre-specified	analyses	versus	post-hoc	analyses
Recommendations and some major points to consider
•	 	First,	find	out	whether	relevant	FDA	approval	packages	are	available	and	how	to	
access them
•	 	When	older	documents	are	not	searchable,	consider	using	text	recognition	
software
•	 	The	medical	review	is	a	key	document	and	good	starting	point
•	 	Try	to	locate	the	table	of	contents	of	an	FDA	approval	document	and	get	familiar	
with the overall document structure
•	 	Identify	pertinent	trials	and	main	information	on	trial	characteristics	and	results	in	
the medical review
•	 	Note	all	trial	names	and	identifiers,	where	possible
•	 	Independent	data	extraction	by	multiple	reviewers	and	noting	the	document	pages	
where information was found may be helpful
•	 	Consider	further	approval	documents	such	as	the	statistical	review,	which	may	
reveal important details
•	 	Re-analyses	by	the	FDA	and	comments	of	the	different	FDA	reviewers	may	provide	
valuable insights for quality of evidence assessment.
•	 	FDA	reviewers	have	a	unique	view	on	the	original	research	data	that	only	a	regulator	
can have
•	 	Redacted	information	is	common	and	requires	special	attention
•	 	Compare	data	extracted	from	approval	information	with	data	from	other	sources
•	 	Always	assess	the	quality	of	evidence	carefully,	which	sometimes	requires	scrutiny	
of the entire approval package to clarify risks of bias
ReseaRch Methods and RepoRting
the bmj | BMJ 2018;362:k2815 | doi: 10.1136/bmj.k2815 5
Recently (March 2018), the FDA announced to 
publish more detailed information, such as Clinical 
Study Reports (CSR). This process is at an early stage, 
and we hope that such promising evidence will be 
available for future drug approvals, but also from drugs 
approved in the past. There is currently the option to 
obtain such CSRs through Freedom of Information Act 
requests.30
Challenges and potential solutions
The reporting quality in FDA approval documents has 
generally improved over time, but inconsistencies and 
contradictions across medical review sections and 
document types occur. Independent data extractions 
by two reviewers may be helpful to overcome this 
problem and to increase the reliability of the data. 
Recording on which document pages the extracted 
information was found may facilitate the consensus 
steps. A general problem of using the approval 
package is missing, inconsistent, or selectively 
reported information. A specific problem is that some 
of the information in FDA reports may be redacted for 
various reasons.15
Schroll and colleagues reported that, in their 
systematic sample of drugs approved between 2011 
and 2012, “crucial information about safety concerns 
and nonapproved indications were redacted in the FDA 
reports.”15 Therefore, utmost attention and careful 
evaluation on a case by case basis is required to assess 
potential biases resulting from incomplete information. 
In this regard, a close evaluation of the concerns of the 
various FDA reviewers in assessing efficacy and safety 
may provide valuable information. Drugs approved 
before 2007 are more prone to suboptimal reporting. 
Options to deal with missing information for outcome 
data include indirect calculation of effect estimates 
of time-to-event endpoints (for example arm-specific 
number of events, point estimates, P values, Kaplan-
Meier curves),31 32 and juxtaposition of the FDA 
approval document information with corresponding 
trial reports in published journal articles, trial 
registries (such as clinicaltrials.gov), or material from 
other approval agencies.
This guidance aims to reduce barriers to use this 
evidence by making access and navigation easier. 
However, important questions remain about how to 
best integrate this valuable source of information into 
evidence syntheses. We touch only briefly on crucial 
subsequent steps of evidence synthesis, for which 
further detailed guidance is needed. In particular, 
thorough assessment of the quality and potential 
biases of the information provided in approval 
documents is indispensable. Overall, we believe that, 
despite such limitations, the consideration of approval 
documents can strengthen evidence syntheses of drug 
interventions.
Parts of this article were presented at the Evidence Live conference 
in Oxford UK (June 21-22, 2017) under the title “Assessing 
drug intervention effects with published FDA approval summary 
documents: an experience report and practical guidance.” We 
thank two colleagues at the University Hospital and University of 
Basel (Dominik Glinz, Basel Institute for Clinical Epidemiology and 
Biostatistics, and Christopher Traenka, Department of Neurology) for 
pilot testing the tutorial.
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